Previous Close | 0.1949 |
Open | 0.1950 |
Bid | 0.0000 x 0 |
Ask | 0.0000 x 0 |
Day's Range | 0.1913 - 0.1980 |
52 Week Range | 0.0560 - 0.2250 |
Volume | |
Avg. Volume | 328,385 |
Market Cap | 80.255M |
Beta (5Y Monthly) | 0.70 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.0100 |
Earnings Date | May 10, 2024 - May 14, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
KNOXVILLE, TN, May 02, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced that the United States Patent and Trademark Office has allowed patent application 17/232,393, titled “Halogenated Xanthene Composition and Method for Treating Hematologic Cancers” (formerly “Composition and Method for Oral Treatment of Leukemia”). The application covers the use of Provectus’s pharmaceutical grade rose bengal sodium (“RBS”) active pharmac
Research on breast, colorectal, head and neck, and testicular cancersNovel downregulation of WNK1 and Wnt signaling KNOXVILLE, TN, April 18, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced that data from preclinical research by the University of Calgary on oral administration of Provectus’s pharmaceutical-grade rose bengal for the treatments of solid tumor cancers were published in the open access journal of oncology Cancer
Names Ed Pershing as Chief Executive Officer and Dominic Rodrigues as President KNOXVILLE, TN, April 16, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced additions to its executive leadership team, reflecting Provectus's dedication to enhancing shareholder value. The Company’s Board of Directors (the “Board”) has appointed Ed Pershing as Chief Executive Officer (“CEO”) and Dominic Rodrigues as President. New Executive Appoin